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Abstract 
Background: Protease inhibitors (PI)s have been associated with distal sensory polyneuropathy (DSP) and metabolic 
complications in high‑income countries. No data exist in Africans where second‑line antiretroviral therapy (ART) often 
include PIs.
Method: We performed a cross‑sectional study to assess the DSP frequency and metabolic risk factors in com‑
munity‑based South Africans taking ritonavir‑boosted lopinavir as PI. Examination findings categorized subjects as 
having DSP (≥1 neuropathic sign) or symptomatic DSP [DSP with symptom(s)]. Fasting‑state glucose and lipid profiles 
were assessed. We compared the ritonavir/lopinavir‑group to a nested group on first‑line ART [dideoxy‑nucleoside 
reverse transcriptase inhibitors (d‑drugs)] selected from a dataset collected at the same time and matched for d‑drug 
exposure.
Results: The ritonavir/lopinavir‑group (n = 86) consisted predominantly of women (84 %) with a median age of 
36 years (IQR 32–41). The median current CD4+ count was 489 cells/μL (IQR 291–665). The median exposure time to 
ritonavir/lopinavir was 18 months (IQR 10–26) and to d‑drugs, 24 months (IQR 16–38). DSP was present in 78 % and 
symptomatic DSP in 48 %; symptoms were most frequently of moderate intensity. Only age independently associated 
with DSP and symptomatic DSP (p = 0.08 and p = 0.04, respectively). None of the metabolic syndrome components 
showed associations with DSP or symptomatic DSP despite a trend towards hypertriglyceridemia overall. The ritona‑
vir/lopinavir‑group had less DSP compared to the d‑drug only group (p = 0.002) but the frequency of symptomatic 
DSP was similar (p = 0.49).
Conclusion: Ritonavir‑boosted lopinavir did not add additional risk to developing DSP in this community‑based 
African cohort after a median of 18 months on second‑line ART.
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Background
Distal sensory polyneuropathy (DSP) is a common neu-
rological complication amongst people living with HIV. 
Reported frequencies of DSP range between 4 and 83 % 
depending on the population studied and the DSP defi-
nition used [1]. The clinical relevance of DSP is that a 
proportion of patients frequently complain of neuro-
pathic symptoms such as pain, paresthesia or numbness 
in the feet which can affect their quality of life, work 
ability and adherence to therapies [1, 2]. Effective treat-
ment is limited. Antiretroviral agents from the dideoxy-
nucleoside reverse transcriptase inhibitor class (d-drugs) 
which includes stavudine and didanosine, are known to 
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associate with the development of symptomatic DSP [1, 
2].
Previously, in a cross-sectional community-based 
sample, we reported a high frequency of DSP among 
South Africans receiving first-line anti-retroviral therapy 
(ART), which at that time, contained stavudine. In align-
ment with the World Health Organization recommen-
dations of the time [3], the South African government 
second-line ART regimen included ritonavir-boosted 
lopinavir (ritonavir/lopinavir) in combination with two 
nucleoside reverse transcriptase inhibitors (NRTI), stavu-
dine or didanosine and lamivudine. Reports from North 
America noted associations between protease inhibitor 
(PI) exposure (indinavir, saquinavir, ritonavir, amprenavir, 
lopinavir) and DSP [4–7]. In addition, PI use among indi-
viduals from developed countries, usually older males, 
has been associated with the development of diabetes 
and hypertriglyceridemia [8, 9], which are also associated 
with DSP [7, 10, 11]. These cohorts differ substantially 
from the vast majority of people presently receiving PIs 
in sub-Saharan Africa; for example, African cohorts are 
young, predominantly women, with very low hepatitis 
C co-infectivity and intravenous drug abuse [12]. There 
are no data on the frequencies of DSP and metabolic 
risk factors in African cohorts on PIs. Here we assessed 
the association between DSP and metabolic factors in a 
community-based South African cohort on second-line 
ritonavir/lopinavir-based ART. Secondly, we compared 
the frequencies of DSP to that of a nested-group who 
had remained on first-line stavudine-containing ART and 
were matched for a similar duration of ART.
Results
Study population characteristics
The ritonavir/lopinavir-group (n = 86) had a median age 
of 36  years and the majority were women (84  %). Their 
median current CD4+ count was 480 cells/μL although 
the nadir pre-ART CD4+ counts were frequently 
<100  cells/μL (Table  1). Overall, these participants had 
been on the government-sponsored ART program for 
a median of 36  months and their median exposure to 
ritonavir/lopinavir was 18 months (IQR 10–28 months). 
In most cases (55 %) second-line ART was started after 
virological failure of first-line regimens and in 26  % it 
was started due to side effects on first-line ART includ-
ing symptomatic hyperlactataemia (presence of nausea, 
vomiting, abdominal pain or weight loss and plasma lac-
tate >2.5 mmol/L) (n =  5), “neuropathy” (n =  4), drug-
induced hepatitis (n  =  4), lipodystrophy (n  =  4) and 
nevirapine-associated rash (n  =  3). Pregnancy resulted 
in a switch to PIs in 7 and in 12  % we were unable to 
determine the reason for changing from first-line ART. 
All participants had previous or current d-drug exposure 
including stavudine (90  %) and/or didanosine (64  %). 
First-line ART at the time of this study comprised sta-
vudine or zidovudine, lamivudine and nevirapine or 
efavirenz. Second-line ART comprised stavudine or dida-
nosine (if stavudine was a first-line agent), lamivudine 
and ritonavir/lopinavir-group. No individuals were tak-
ing statins or concomitant oral hypoglycemic agents.
Frequencies and risk factors of distal sensory 
polyneuropathy
DSP was present in 67 (78 %) of individuals in the rito-
navir/lopinavir-group and symptomatic DSP in 41 (48 %) 
(Table  1). Pain and/or paresthesiae were more frequent 
complaints than numbness (78 vs. 66 %) and the symp-
tom severity grade was most often classified as moder-
ate (Additional file  1: Table S1). Altered reflexes, either 
reduced or absent, was the most frequent neuropathic 
findings in both DSP (73 %) and symptomatic DSP (85 %), 
altered distal vibration sense in 63–64 % of subjects and 
impaired distal pain sensibility in 37–39 % of those with 
DSP and symptomatic DSP, respectively. Mild/moderate 
weakness of the toes/ankles was present in ≤25 %.
Those with DSP were older (37 vs. 33 years, p = 0.007) 
with lower current CD4+ counts (418 vs. 576  cells/
µl, p  =  0.030) although their nadir CD4+ counts were 
similar to those without DSP. In addition, subjects with 
DSP compared to those without DSP had lower macro-
nutritional indicators including bodyweight (64 vs. 95 kg; 
p < 0.001), body mass index (BMI) (25.1 vs. 34.5 kg/m2; 
p =  0.005) and waist circumference (85.0 vs. 103.7  cm; 
p  =  0.001). Obesity (BMI >30  kg/m2) was present in 
22  % of the DSP group and 54  % of those without DSP 
(p  =  0.009). A multivariate logistic regression model 
found none of these factors independently associated 
with DSP although a trend remained with those older 
than 36 years (p = 0.08; Table 2).
Symptomatic DSP also showed significant associations 
with age (p = 0.007) and lower macro-nutritional indica-
tors including bodyweight (p = 0.008), BMI (p = 0.018) 
and waist circumference (p = 0.017), but on multivariate 
analyses only age remained as an independent risk fac-
tor (p = 0.042; Table 2). A history of previous tuberculo-
sis infection(s) showed a trend towards associating with 
symptomatic DSP (p = 0.059).
Metabolic factors and distal sensory polyneuropathy
Dysglycemia was found in 41  % of the ritonavir/lopi-
navir-group although neither the fasting glucose nor 
OGTT values associated with DSP or symptomatic DSP 
(Table  1). Hypertriglyceridemia, defined as fasting tri-
glycerides ≥1.7 mmol/L (≥150 mg/dl), was found in 29 %, 
but fasting triglyceride levels did not show an association 
with neuropathy status (Table 2). Low density lipoprotein 
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(LDL) levels were not associated with DSP but individu-
als with symptomatic DSP had a trend (p = 0.06) towards 
lower values.
Protease inhibitors + d‑drugs vs. d‑drugs only and the risk 
of distal sensory polyneuropathy
As reports from high-income countries previously 
alluded to an additional risk of PIs and DSP we next com-
pared the frequencies of DSP in this ritonavir/lopinavir-
group who had prior exposure to NRTI-drugs as first-line 
therapy, and a nested NRTI-group remaining on first-line 
ART but matched for overall d-drug exposure (Table 3). 
Although the two groups had similar age distributions 
(p  =  0.57) they differed in several aspects; the ritona-
vir/lopinavir-group had proportionately more women 
(p =  0.019), lower nadir CD4+ counts (p =  0.044) and 
higher lactate levels (p  =  0.013). The ritonavir/lopina-
vir-group was taller (1.62 vs. 1.51  m; p  <  0.0001) with 
lower BMI values (p =  0.036) but they had larger waist 
circumference values (p  =  0.029). The ritonavir/lopi-
navir-group had higher fasting triglyceride levels (1.29 
vs. 1.10 mmol/L, p =  0.021) and more participants met 
criteria for hypertriglyceridemia (29 vs. 12 %, p = 0.031). 
However, the proportion of participants with DSP was 
lower in the ritonavir/lopinavir-group (78 %) when com-
pared with the nested d-drug only group (94  %; odds 
ratio =  0.22; 95  % CI 0.07–0.6; p =  0.002) and the fre-
quencies of symptomatic DSP were similar in both 
groups (48 vs. 53 %, p = 0.49).
Discussion
We present the first cross-sectional evaluation of the fre-
quency and risk factors of DSP in a HIV-infected African 
cohort receiving the protease inhibitor, ritonavir/lopina-
vir, as second-line ART for approximately 12–24 months. 
The frequency of DSP (using the non-stringent but 
standard definition) was high at 78  %, but importantly, 
almost half of the cohort (48  %) had symptomatic DSP. 
Table 1 Clinical and laboratory characteristics of DSP and symptomatic DSP in the ritonavir/lopinavir-group (n = 86)
All continuous variables shown as median value (inter quartile range). Pre-diabetes defined as fasting plasma glucose (FPG) ≥5.6 mmol/L but <7.0 mmol/L or 2-h 
plasma glucose during the oral glucose tolerance test [OGTT] ≥7.8 mmol/L but <11.1 mmol/L. Diabetes defined as FPG ≥7.0 mmol/L or 2-h OGTT ≥11.1 mmol/L
DSP distal sensory polyneuropathy, defined by the presence of ≥1 neuropathic sign, symptomatic DSP DSP in the presence ≥1 neuropathic symptom, Mo. months, 
LPV/r ritonavir/lopinavir
Italic values indicate statistically significant P values
a Any alcohol use in the past 12 months. P values for DSP and symptomatic DSP derived by comparing with no DSP
Normal value No DSP (n = 19) DSP (n = 67) P value Symptomatic DSP (n = 41) P value
Age, years 33 (27–36) 37 (33–43) 0.007 37 (34–42) 0.007
Female, n (%) 17 (89) 55 (82) 0.45 33 (80) 0.39
Alcohola, n (%) 8 (42) 21 (32) 0.41 14 (34) 0.55
Previous TB, n (%) 12 (63) 49 (74) 0.35 35 (85) 0.059
Total d‑drug exposure, mo. 26 (12–36) 24 (18–38) 0.67 22 (15–39) 0.53
Stavudine exposure, mo. 15 (11–34) 15 (10–22) 0.33 15 (8–25) 0.32
Didanosine exposure, mo. 19 (12–21) 13 (7–23) 0.24 13.5 (7–25.5) 0.29
LPV/r exposure, mo. 21 (12–35) 18 (10–26) 0.08 18 (10–26) 0.24
CD4 nadir, cells/µL 84 (54–180) 96 (37–122) 0.28 68 (25–120) 0.13
CD4 current, cells/µL 576 (467–726) 418 (251–610) 0.030 472 (251–752) 0.15
Viral load at ART initiation 184,563 (30,438–244,623) 96,645 (36,820–241,495) 0.54 108,572 (36,858–280,000) 0.92
Height (m) 1.64 (1.63–1.66) 1.61 (1.56–1.65) 0.15 1.62 (1.58–1.68) 0.45
Weight (kg) 95 (70–98) 64 (57–76) <0.001 68.5 (59.9–82) 0.008
Body mass index (kg/m2) <25 34.5 (26.0–38.5) 25.1 (23.3–29.5) 0.005 26.1 (23.26–30.29) 0.018
Waist circumference (cm) 103.7 (92.5–109.5) 85.0 (78.5–93.5) 0.001 87.0 (78.5–99) 0.017
Systolic blood pressure 
(mmHg)
110 (103–125) 107 (102–109) 0.13 107 (102–119) 0.15
Pre‑diabetes, n (%) 5 (26) 22 (33) 0.59 11 (27) 0.97
Diabetes, n (%) 2 (11) 6 (9) 0.84 4 (10) 0.93
Total cholesterol (mmol/L) <5.17 4.58 (4.13–5.49) 4.33 (3.69–5.35) 0.56 3.98 (3.66–5.05) 0.20
HDL (mmol/L) >1.03 0.93 (0.75–1.20) 0.99 (0.80–1.17) 0.79 0.98 (0.76–1.17) 0.99
LDL (mmol/L) <2.60 3.18 (2.66–3.39) 2.56 (2.18–3.14) 0.21 2.46 (2.12–3.00) 0.06
Triglycerides (mmol/L) <1.70 1.23 (0.97–1.57) 1.36 (0.89–1.92) 0.91 1.29 (0.93–1.79) 0.79
Fasting lactate (mmol/L) <1.5 2.3 (1.5–2.9) 2.1 (1.7–2.8) 0.73 2.2 (1.7–3.0) 0.81
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In contrast, after a similar period of ART, North Ameri-
can cohorts showed DSP frequencies of ≈32–50  % and 
symptomatic DSP of ≈20  % [7]. Interestingly, we found 
that a comparator d-drug only group matched for the 
duration of d-drug exposure as first-line ART, showed 
similar frequencies of symptomatic DSP. This suggests 
that the PI-regimen was not conferring additional risk 
to developing DSP. An important aim of this study was 
to investigate the association of DSP and metabolic fac-
tors given the potential of ritonavir/lopinavir to induce 
dysglycemia and dyslipidemia [8]. However, we found no 
associations between these metabolic factors and DSP or 
symptomatic DSP.
This African cohort had relatively advanced HIV-
disease when starting ART, and after 2–3 years on ART, 
older age was the only independent risk factor for symp-
tomatic DSP. Advancing age remains the most consistent 
factor associated with DSP and symptomatic DSP in both 
ART-naïve and ART-exposed cohorts irrespective of 
the ART regimen [1, 2, 7, 13, 14]. In many HIV-infected 
cohorts comprising mostly of men, height has been asso-
ciated with symptomatic DSP [14, 15]. We have not found 
this association in either a previous [2], or this current 
cohort, both of which consisted mostly of indigenous 
black South African women. Similar to previous reports 
from Africa, a previous history of tuberculosis was again 
shown to segregate with symptomatic DSP [2, 16]. There 
are multiple reasons why HIV/TB co-infected individu-
als might be at greater risk of DSP including treatment 
with isoniazid, micronutrient deficiencies including inad-
equate pyridoxine supplementation and the cumulative 
oxidative stress of HIV/TB co-infection [16–19].
The broader applicability of our results in the current 
era of ART has several constraints; firstly, similar to many 
HIV-infected cohorts in sub-Saharan Africa and differ-
ing from the developed world, few individuals in this 
cohort are older than 40 years. Our participants are pre-
dominantly young women and although HIV-infection 
is expected to accelerate ageing and impact on the meta-
bolic syndrome it may still be too early for the metabolic 
manifestations of ART. In contrast to our findings, cross-
sectional North American studies found elevated random 
[11] and fasting [10] triglyceride levels to be associated 
with DSP but these cohorts consisted mostly of older 
men.
Conclusions
Despite high frequencies of DSP and symptomatic DSP 
among South Africans receiving ritonavir-boosted lopi-
navir (for a median of 18 months) following prior expo-
sure to stavudine-containing ART, our result show that 
this protease inhibitor, was not associated with additional 
risk of developing DSP. Although we found no asso-
ciation between DSP and metabolic factors after at least 
12 months of exposure to protease inhibitors in this rela-
tively young cohort of mostly black women, longer-term 




The participants for this cross-sectional study were 
recruited between 2008 and 2010 from two commu-
nity healthcare centers in Cape Town, South Africa. The 
South African governmental HIV treatment program at 
the time, used the PI, ritonavir/lopinavir as part of their 
second-line ART in combination with two NRTI-class 
drugs. Eligible subjects had to be on ritonavir/lopinavir-
containing second-line ART for ≥6 months. Participants 
were excluded if they had: a history of diabetes melli-
tus; active opportunistic infection; severe diarrhea (six 
Table 2 Multivariate analysis of  risk factors for  DSP 
and symptomatic DSP in the ritonavir/lopinavir-group
DSP distal sensory polyneuropathy, defined by the presence of ≥1 neuropathic 
sign, symptomatic DSP DSP in the presence ≥1 neuropathic symptom, BMI body 
mass index
a Defined as a waist circumference of >88 cm for women and >102 cm for men
Univariate analysis Multivariate analysis
Odds ratio  
(95 % CI)




 Age >36 years
  Yes 3.9 (1.26–12.08) 0.018 7.0 (0.88–55.65) 0.08
  No 1
 BMI < 30 kg/m2
  Yes 6.19 (1.56–24.47) 0.009 0.38 (0.03–5.37) 0.47
  No 1
 Waist circumference increaseda
  Yes 0.18 (0.54–0.60) 0.005 1.33 (0.11–15.5) 0.82
  No 1
 Current CD4 count <250 cells/μL
  Yes 5.88 (0.73–47.58) 0.09 0.43 (0.03–6.20) 0.54
  No 1
 Symptomatic DSP
  Age  
>36 years
  Yes 4.38 (1.32–14.50) 0.016 7.39 (1.07–50.77) 0.042
  No 1
 BMI <30 kg/m2
  Yes 4.14 (1.00–17.05) 0.049 0.38 (0.03–5.62) 0.38
  No 1
 Waist circumference increaseda
  Yes 0.23 (0.06–0.81) 0.023 1.86 (0.12–29.60) 0.66
  No 1
Page 5 of 7Vermaak et al. AIDS Res Ther  (2015) 12:30 
stools/day); tuberculosis <1 month of commencing treat-
ment; received glucocorticoid therapy within the past 
6 months; pregnant; known with renal failure; neurologi-
cal disorder confounding the assessment of neuropathy. 
The study was approved by the University of Cape Town 
Research Ethics Committee.
After signing informed consent, study participants 
were assessed by one of two trained doctors using the 
Brief Peripheral Neuropathy Screen (BPNS) and a revi-
sion of the modified Total Neuropathy Score (TNSr) as 
previously described [2, 20]. Supervision of examination 
procedures by a neurologist was frequent and ongo-
ing throughout the study period. The definition for DSP 
included the symmetrical distal onset of ≥1 neuropathic 
sign in the feet: reduced/absent reflexes, impaired distal 
vibration or pin sensibility. Symptomatic DSP referred to 
DSP with symmetrical neuropathic symptoms: burning 
pain, paresthesiae or numbness. Symptom severity was 
assessed using a visual numerical scale ranging between 
0 and 10 and then graded as mild (1–3), moderate (4–6), 
severe (7–8) and very severe (9–10). Blood pressure and 
anthropometry (weight, BMI, waist circumference), as 
well as an oral glucose tolerance test (OGTT) and fast-
ing lipid levels were performed as previously described 
[21]. Pre-diabetes was defined as fasting plasma glucose 
(FPG) ≥5.6  mmol/L but <7.0  mmol/L or 2-h OGTT 
plasma glucose ≥7.8  mmol/L but <11.1  mmol/L. Dia-
betes was defined as FPG ≥7.0  mmol/L or 2-h OGTT 
≥11.1 mmol/L. Demographic information including drug 
history was obtained by questionnaire and folder review.
Table 3 Demographics and clinical features in the ritonavir/lopinavir-group compared to the NRTI-only nested control-
group
The results of all continuous variables are shown as median (inter quartile range). DSP distal sensory polyneuropathy as defined by ≥1 neuropathic sign. Symptomatic 
DSP is defined as ≥1 neuropathic sign and symptom. Prediabetes defined as fasting plasma glucose (FPG) ≥5.6 mmol/L but <7.0 mmol/L or 2-h plasma glucose 
during the oral glucose tolerance test (OGTT) ≥7.8 mmol/L but <11.1 mmol/L. Diabetes defined as FPG ≥7.0 mmol/L or 2-h plasma glucose during the OGTT 
≥11.1 mmol/L
a The nested controls were extracted from a cohort [2] as outlined in Methods
b Any alcohol use in the prior 12 months
c Defined as the sum of stavudine and didanosine exposure times
d Men <90 cm, women <84 cm. P value reflects the comparison of those exposed to ritonavir/lopinavir vs. the matched controls who did not have ritonavir/lopinavir 
exposure
Normal value Ritonavir/lopinavir D‑drug onlya P value
n = 86 n = 85
Age, years 35 (32–41) 36 (30–42) 0.57
Female, n (%) 72 (84) 58 (68) 0.019
Previous tuberculosis, n (%) 61 (72) 58 (74) 0.71
Alcohol usage, n (%)b 29 (34) 21 (25) 0.18
Period on d‑drugs, monthsc 24 (16–37.5) 23 (18–28) 0.33
DSP, n (%) 67 (78) 80 (94) 0.004
Symptomatic DSP, n (%) 41 (48) 45 (53) 0.49
Height (m) 1.62 (1.57–1.65) 1.51 (1.44–1.57) <0.001
Weight (kg) 67 (59–85) 66 (58–75) 0.10
Body mass index <25 26.0 (23.6–30.9) 30.0 (24.0–34.0) 0.036
Waist circumference (cm)d 87.8 (79.3–100.3) 83.8 (77.5–92.0) 0.029
Systolic BP (mmHg) 108 (102–119) 108 (100–116) 0.81
CD4 current (cells/µL) 489 (291–665) 406 (296–564) 0.49
CD4 nadir (cells/µL) 96 (37–132) 120 (55–160) 0.044
Viral load at start of ARV 102,268 (36,820–241,495) 53,000 (12,000–360,000) 0.51
Pre‑diabetes, n (%) 27 (32) 27 (39) 0.24
Diabetes, n (%) 8 (9) 3 (4) 0.35
Total cholesterol (mmol/L) <5.17 4.42 (3.75–5.41) 4.31 (3.45–4.83) 0.11
HDL (mmol/L) <1.03 0.96 (0.76–1.17) 0.97 (0.79‑1.18) 0.90
Triglycerides (mmol/L) <1.70 1.29 (0.93–1.82) 1.10 (0.80–1.47) 0.021
Hypertriglyceridemia, N (%) >1.70 25(29) 10 (12) 0.031
Fasting lactate (mmol/L) <1.5 2.2 (1.7–2.9) 1.8 (1.4–2.4) 0.013
Hyperlactatemia, N (%) >2.5 32 (39) 20 (25) 0.06
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For comparison, a nested-group on first-line ART (con-
taining the d-drug, stavudine) were selected from a pre-
viously described cross-sectional cohort [2] who were 
recruited from the same clinics, according to the same 
inclusion/exclusion criteria and underwent evaluations 
according to the same protocol by the same study team. 
Although there was some overlap in the study period, this 
second-line ART study started at least 12  months after 
the first-line study. The groups were matched for dura-
tion of ART and d-drug exposure in the following man-
ner: all subjects on first-line ART (n = 216) and shorter 
total d-drug exposure times were systematically censored 
until there was no statistical difference in the exposure 
times between the nested d-drug cohort and the ritona-
vir/lopinavir-group. This point was reached when d-drug 
exposure ≥14 months and included 85 subjects.
Statistical analysis
For univariate analyses continuous variables were 
assessed by Shapiro–Wilk testing and non-parametric 
data was transformed by the most appropriate trans-
formation selected from a ladder of powers of trans-
formations. Student t tests were used for parametric 
continuous data, Wilcoxon rank-sum tests for non-
transformable non-parametric data and Chi square tests 
for categorical data. Statistical significance was set at the 
0.05 level (two-sided). Certain continuous variables were 
categorized based on clinically relevant cutoff values. 
Variables showing significant associations were systemat-
ically included in a step- wise multivariate logistic regres-
sion model. Spearman correlates were used to investigate 
the relationship between the variables included in each 
model. All data analyses were performed using STATA/
IC 11.
Abbreviations
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fasting plasma glucose; BMI: body mass index.
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